MAP2K7 and melanoma: As noted above, a limitation of the study was the use of a BRAF/MEK inhibitor combination for this proof-of-concept study, which was based on the availability of established dosing and safety data for this regimen from patients with melanoma at the time that this study was initiated; this preceded the results of the BEACON study that demonstrated the efficacy of encorafenib and cetuximab in this population.